Experience with imatinib to treat pulmonary arterial hypertension

Archivos de Bronconeumologia

Volumn 44, Issue 12, 2008, Pages 689-691

  García Hernández, Francisco José ^a,b   Palma, María Jesús Castillo ^a   León, Rocío González ^a   Rasco, Rocío Garrido ^a   Medina, Celia Ocaña ^a   Román, Julio Sánchez ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE   (Spain)

Author keywords

Imatinib; Pulmonary arterial hypertension; Toxicity

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; BOSENTAN; DIGOXIN; DIURETIC AGENT; FUROSEMIDE; ILOPROST; IMATINIB; PROPYLTHIOURACIL; PROSTACYCLIN; SILDENAFIL; UNIPROST; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PYRIMIDINE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTHYROIDISM; LABORATORY TEST; LIVER TOXICITY; LUNG ARTERY PRESSURE; PULMONARY HYPERTENSION; TREATMENT OUTCOME; DRUG ANTAGONISM; FATALITY; MIDDLE AGED; TOXIC HEPATITIS;

ADULT; FATAL OUTCOME; FEMALE; HEPATITIS, TOXIC; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES;

EID: 58049202344     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(09)60008-2     Document Type: Article

References (23)

1. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation. 2002;106:1477-82.
2. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
3. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur Respir J. 2006;28:1195-203.
4. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006;36 Suppl 3:10-5.
5. Román A, Gispert P, Monforte V, Bravo C, Domingo E, Morell F. Resultados a largo plazo del tratamiento con bosentán en la hipertensión arterial pulmonar. Arch Bronconeumol. 2006;42:616-20.
6. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
7. Otero González I, Blanco Aparicio M, Souto Alonso A, Raposo Sonnenfeld I, Verea Hernando H. Hipertensión pulmonar: eficacia clínica del sildenafilo en clases funcionales II-III. Arch Bronconeumol. 2007;43:272-6.
8. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26:858-63.
9. García Hernández FJ, Ocaña Medina C, Mateos Romero L, Martínez Martínez A, Bautista Lorite A, Santos Ramos B, et al. Tratamiento combinado con prostaciclina intravenosa y sildenafilo en pacientes con hipertensión pulmonar. Descripción de 4 casos. Med Clin (Barc). 2004;122:64-6.
10. Baloira A. Futuro del tratamiento de la hipertensión pulmonar. Arch Bronconeumol. 2007;43:131-5.
11. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005;115:2691-4.
12. Balasubramaniam V, le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2003;284:L826-L33.
13. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11:554-9.
14. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-21.
15. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-3.
16. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006;145:152-3.
17. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax. 2006;61:736.
18. Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica. 2006;91 6 Suppl:ECR27.
19. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-42.
20. Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455-6.
21. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160-1.
22. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978-9.
23. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol. 2005;39:75-7.